Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Alcon AG Stock

Price
Target price
€67.12

€67.12

-2.070%
-1.42
-2.070%
-
 
11.12.25 / Tradegate WKN: A2PDXE / Name: Alcon / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Alcon AG in the next few years
Wizard

Financial data and news for Alcon

sharewise wants to provide you with the best news and tools for Alcon, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval


Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This

BusinessWire_EN 
0 08.07.25
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL


Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients

BusinessWire_EN 
0 20.06.25
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)


Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for

BusinessWire_EN 
0 07.07.25
Alcon Canada Earns Global Recognition as a Top Employer
Alcon Canada Earns Global Recognition as a Top Employer


Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a

BusinessWire_EN 
0 26.06.25